Within3 Raises $100M For Virtual Clinical Communication App

Within3, a virtual clinical communication app for pharmaceutical and other life sciences companies, closed a $100 million growth funding round led by Insight Partners, with participation from Silversmith Capital Partners.

Aeris Partners served as the exclusive financial advisor to Within3. Willkie Farr & Gallagher served as legal advisors to Insight, and Kirkland and Ellis represented Silversmith Capital Partners.

According to the company, the funding will accelerate product innovation, build infrastructure to outpace growing demand, and fuel international expansion.

Life science companies – including the top 20 pharmaceutical manufacturers – use the app to engage healthcare providers, patients, payers, and other stakeholders in more than 150 countries, and according to the company. The app enables global collaboration to bring drugs to market more quickly, publish clinical studies, host advisory boards, and engage virtually on any business initiative with multi-stakeholder involvement.

Lance Hill, CEO of Within3, said: “Global demand for our solution is surging at an unprecedented rate. Life science companies are looking for virtual work solutions that exceed the level of engagement of traditional live interactions, meet all their compliance needs, and that will scale across the enterprise. They have found that solution with Within3.”

“The funding will allow us to accelerate our growth and product pipeline to continue to meet the growing demand from the market. We will be able to accelerate new innovations in our product roadmap and bring our customers smarter, more innovative solutions faster,” added Lance Hill.

Within3, founded in 2008, has secured an undisclosed amount of funding in 2012, from Easton Capital. The company employs more than 50 people with an office in Lakewood, Ohio.

mHealth apps have raised almost $800 million in the first half of 2020, according to Mercom’s latest funding report. Recently, Datacubed Health (Datacubed), an end-to-end digital clinical trial platform, announced an investment from Sterling Partners, an investment firm focused on transformational growth.

Image Credit: Within3